Table 5:
The treatment response and clinical outcomes in our AML cohort of patients with del(7q) only treated with or without Venetoclax with or without TP53 alterations.
| Characteristic | Overall, N = 59 | del(7q) Tp53-alt1, Others N = 33 | del(7q) Tp53-alt1, Ven N = 5 | del(7q) Tp53-wt1, Others N = 18 | del(7q) Tp53-wt1, Ven N = 3 | p-value2 |
|---|---|---|---|---|---|---|
| Age (years), Mean+/−SD; Median (Range) | 70.1+/−12.1; 72.3 (25.0 – 84.2) | 72.5+/−10.0; 73.1 (33.9 – 84.2) | 67.6+/−6.9; 65.0 (59.3 – 76.1) | 65.7+/−16.2; 70.0 (25.0 – 83.9) | 73.9+/−3.9; 72.3 (71.0 – 78.3) | 0.3 |
| Gender, n/N (%) | 0.037 | |||||
| Female | 19/59 (32%) | 12/33 (36%) | 3/5 (60%) | 2/18 (11%) | 2/3 (67%) | |
| Male | 40/59 (68%) | 21/33 (64%) | 2/5 (40%) | 16/18 (89%) | 1/3 (33%) | |
| Cytogenetics, n/N (%) | <0.001 | |||||
| Complex (>=3) | 42/59 (71%) | 33/33 (100%) | 5/5 (100%) | 3/18 (17%) | 1/3 (33%) | |
| Other (<3) | 17/59 (29%) | 0/33 (0%) | 0/5 (0%) | 15/18 (83%) | 2/3 (67%) | |
| ELN based on Cytogenetics, n/N (%) | <0.001 | |||||
| Non-poor | 17/59 (29%) | 0/33 (0%) | 0/5 (0%) | 15/18 (83%) | 2/3 (67%) | |
| Poor | 42/59 (71%) | 33/33 (100%) | 5/5 (100%) | 3/18 (17%) | 1/3 (33%) | |
| Secondary AML, n/N (%) | 0.4 | |||||
| De novo AML | 35/59 (59%) | 19/33 (58%) | 2/5 (40%) | 13/18 (72%) | 1/3 (33%) | |
| Secondary AML | 24/59 (41%) | 14/33 (42%) | 3/5 (60%) | 5/18 (28%) | 2/3 (67%) | |
| TP53 Mutations, n/N (%) | <0.001 | |||||
| TP53 wild type | 25/54 (46%) | 4/28 (14%) | 0/5 (0%) | 18/18 (100%) | 3/3 (100%) | |
| TP53 mutant | 29/54 (54%) | 24/28 (86%) | 5/5 (100%) | 0/18 (0%) | 0/3 (0%) | |
| Unknown | 5 | 5 | 0 | 0 | 0 | |
| Chr17/17p Loss, n/N (%) | 21/59 (36%) | 19/33 (58%) | 2/5 (40%) | 0/18 (0%) | 0/3 (0%) | <0.001 |
| Venetoclax, n/N (%) | <0.001 | |||||
| Others | 51/59 (86%) | 33/33 (100%) | 0/5 (0%) | 18/18 (100%) | 0/3 (0%) | |
| Venetoclax | 8/59 (14%) | 0/33 (0%) | 5/5 (100%) | 0/18 (0%) | 3/3 (100%) | |
| Intensity, n/N (%) | 0.2 | |||||
| High Intensity | 13/59 (22%) | 5/33 (15%) | 1/5 (20%) | 7/18 (39%) | 0/3 (0%) | |
| Low Intensity | 46/59 (78%) | 28/33 (85%) | 4/5 (80%) | 11/18 (61%) | 3/3 (100%) | |
| Best Response, n/N (%) | 0.14 | |||||
| CR | 22/59 (37%) | 12/33 (36%) | 3/5 (60%) | 6/18 (33%) | 1/3 (33%) | |
| CRi | 6/59 (10%) | 2/33 (6.1%) | 0/5 (0%) | 2/18 (11%) | 2/3 (67%) | |
| NR | 31/59 (53%) | 19/33 (58%) | 2/5 (40%) | 10/18 (56%) | 0/3 (0%) |
1
P53-alt indicates patients with TP53 mutations, chr17 loss, or chr17p loss
2
Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test